RWLK VS CELU Stock Comparison

Performance

RWLK
10/100

RWLK returned -33.16% in the last 12 months. Based on SPY's performance of -21.08%, its performance is below average giving it a score of 10 of 100.

CELU
10/100

CELU returned -89.49% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

RWLK
80/100

5 analysts offer 12-month price targets for RWLK. Together, they have an average target of 3, the most optimistic target put RWLK at 3 within 12-months and the most pessimistic has RWLK at 3.

CELU

"Analyst Price Targets" not found for CELU

Sentiment

RWLK
70/100

RWLK had a bullish sentiment score of 69.59% across Twitter and StockTwits over the last 12 months. It had an average of 16.27 posts, 18.18 comments, and 54.60 likes per day.

CELU

"Sentiment" not found for CELU

Technicals

RWLK
10/100

RWLK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

CELU
10/100

CELU receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

RWLK
10/100

RWLK has missed earnings 12 times in the last 20 quarters.

CELU
51/100

CELU has missed earnings 2 times in the last 20 quarters.

Profit

RWLK
10/100

Out of the last 20 quarters, RWLK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CELU
45/100

Out of the last 18 quarters, CELU has had 9 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

RWLK
44/100

RWLK has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

CELU
32/100

CELU has had a lower than average amount of volatility over the last 12 months giving it a score of 31 of 100.

All score calculations are broken down here to help you make more informed investing decisions

ReWalk Robotics Ltd Summary

Nasdaq / RWLK

Healthcare

Medical Devices

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

Celularity Inc. Class A Common Stock Summary

Nasdaq / CELU

Healthcare

Biotechnology

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Power up your portfolio